BridgeBio Pharma (BBIO) EBITDA (2018 - 2026)
BridgeBio Pharma recorded quarterly EBITDA of -$106.0 million in Q1 2026, up 24.08% quarter-over-quarter from -$139.6 million in Q4 2025, and down 1.52% year-over-year from -$107.6 million in Q1 2025.
BridgeBio Pharma's EBITDA history runs 9 years deep, the most recent figure standing at -$106.0 million for Q1 2026.
- In Q1 2026, EBITDA fell 1.52% year-over-year to -$106.0 million; the TTM figure through Mar 2026 stood at -$525.0 million (up 24.75% YoY), while the FY2025 annual figure was -$523.4 million, up 11.73% from the prior year.
- EBITDA came in at -$106.0 million for Q1 2026 at BridgeBio Pharma, up from -$139.6 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $343000.0 in Q1 2024 to a low of -$226.0 million in Q4 2024.
- A 5-year average of -$137.8 million and a median of -$139.6 million in 2025 frame the typical range for EBITDA.
- Across the five-year window, EBITDA soared 100.27% in 2024 and tumbled 30529.15% in 2025, its largest moves.
- BridgeBio Pharma's EBITDA stood at -$129.2 million in 2022, then tumbled by 37.28% to -$177.4 million in 2023, then fell by 27.4% to -$226.0 million in 2024, then soared by 38.25% to -$139.6 million in 2025, then gained by 24.08% to -$106.0 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$106.0 million, -$139.6 million, and -$145.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -105.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -105.96 Mn |
| Dec 31, 2025 | -139.56 Mn |
| Sep 30, 2025 | -145.20 Mn |
| Jun 30, 2025 | -134.28 Mn |
| Mar 31, 2025 | -104.37 Mn |
| Dec 31, 2024 | -226.03 Mn |
| Sep 30, 2024 | -191.75 Mn |
| Jun 30, 2024 | -175.54 Mn |
| Mar 31, 2024 | 343,000.00 |
| Dec 31, 2023 | -177.42 Mn |
| Sep 30, 2023 | -157.69 Mn |
| Jun 30, 2023 | -146.10 Mn |
| Mar 31, 2023 | -126.16 Mn |
| Dec 31, 2022 | -129.23 Mn |
| Sep 30, 2022 | -129.12 Mn |
| Jun 30, 2022 | -80.18 Mn |
| Mar 31, 2022 | -173.68 Mn |
| Dec 31, 2021 | -165.61 Mn |
| Sep 30, 2021 | -149.50 Mn |
| Jun 30, 2021 | -94.02 Mn |
| Mar 31, 2021 | -167.50 Mn |
| Dec 31, 2020 | -127.49 Mn |
| Sep 30, 2020 | -119.94 Mn |
| Jun 30, 2020 | -124.57 Mn |
| Mar 31, 2020 | -102.49 Mn |
| Dec 31, 2019 | -78.64 Mn |
| Sep 30, 2019 | -54.53 Mn |
| Jun 30, 2019 | -69.32 Mn |
| Mar 31, 2019 | -7.46 Mn |
| Dec 31, 2018 | -65.58 Mn |
| Sep 30, 2018 | -41.46 Mn |
| Jun 30, 2018 | -34.78 Mn |